Request for Investigator Initiated Study (IIS) Proposal – Pressure Injury Prevention (PIP) utilizing a Clinician Endorsed Facility Protocol within At-Risk Acute Care Patients

Summary

Smith+Nephew is interested in receiving proposals for investigating the use of a combination of prophylactic therapies for pressure injury prevention in at-risk acute care patients.

Products

LEAF° Patient Monitoring System and ALLEVYN° LIFE Foam Dressing and SECURA° Skin Care

Topics of Interest

We are interested in comparing clinical outcomes before and after implementation of a clinician endorsed facility protocol for pressure injury prevention (PIP) that includes the use of the LEAF° Patient Monitoring System, ALLEVYN° LIFE Foam Dressings, and SECURA° Skin Care.

Patients should be screened and identified as at-risk for pressure injury development. The three therapies must be applied in an acute care setting. Outcomes of interest include hospital acquired pressure injury incidence; overall cost of care, including treatment costs; nursing key performance indicators of protocol and qualitative feedback such as healthcare professional satisfaction, teamwork, and communication. A minimum period of 6 months of clinical and economic outcomes, showing the effectiveness of the PIP protocol would be desirable.

The scope of this RFP is limited to clinical research and does not include in vitro laboratory-based research. Applications for funding will only be considered in which all products/devices are used in accordance with the cleared Indications for Use.

Regional considerations

For commercial reasons we are only interested in applications from the US at this time.

Contact information

This RFP has been posted on the S+N IIS website: https://www.smith-nephew.com/en/investigator-initiated-studies

All application submission information relating to this RFP can be located on the above website and your application can be submitted electronically to the following email: studyrequest@smith-nephew.com

Deadline for submission

31 December 2023